The Silicon Review
Precision medicine also called as predictive genomics is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person. This approach will allow doctors and researchers to predict more accurately which treatment and prevention strategies for a particular disease will work in which groups of people. It is in contrast to a one-size-fits-all approach, in which disease treatment and prevention strategies are developed for the average person, with less consideration for the differences between individuals. Although the term "precision medicine" is relatively new, the concept has been a part of healthcare for many years. It is a powerful capability that can help predict disease risk and understand drug response in order to focus health care resources on improving outcomes and managing costs.
Founded by Johns Hopkins researchers and serial entrepreneurs, Predictiv is a ground-breaking genomics-based solution to reinvent medicine. Predictiv uses a unique technology that provides a DNA-Based digital twin for health that analyzes a patient's whole genome to predict and prevent risks on more than 22,000 diseases and simulate reactions to 750 drugs. Predictiv plans to provide health and analytical data on virtually all aspects of health. While they are starting with genomic sequencing and genetic testing, they plan to launch a fully scaled health and medical data platform, which will also bring the world of nutrition and fitness into the future.
Predictiv enables Genetic Disorder Prediction
For each organism, DNA is a complex and information-loaded building block of cells. Using DNA to create digital twins allows scientists to plan personalized medical treatments for an individual. This, in turn, makes any future issues predictable and also preventable. Although digital twin technology is still evolving, it already advances medical and surgical applications through virtual trials to improve patient safety. Predictiv predicts occurrences of serious and genetic disorders in an individual using their DNA-based digital twin. The startup collects an individual’s fingernails to extract their DNA and build digital twins. They then prepare a genetic risk assessment report and provide preventive healthcare plans personalized for each individual.
Personalized Medicine Approach
Predictiv’s personalized medicine (PM) is about tailoring a treatment as individualized as the disease. The approach relies on identifying genetic, epigenomic, and clinical information that allows the breakthroughs in its understanding of how a person’s unique genomic portfolio makes them vulnerable to certain diseases. PM approach is a complete extension of traditional approach (One-Size-Fits-All) to increasing the ability to predict which medical treatments will be safe and effective for individual patient, and which ones will not be, based on the patient’s unique genetic profile. Implementation of PM has the potential to reduce financial and time expenditure, and increase quality of life and life extension of patients. Knowledge of PM facilitates earlier disease detection via enhanced use of existing biomarkers and detection of early genomic and epigenomic events in disease development, particularly carcinogenesis. The PM approach predominantly focuses on preventative medicine and favors taking pro-active actions rather than just reactive. This approach delays or prevents the need to apply more severe treatments which are usually less tolerated and with increased quality of life and financial considerations.
The revolution of PM has created a lucrative opportunity for pharmaceutical companies developing molecular-targeted therapeutics, but also through the optimized use and repurposing of existing drugs and combination therapies. Adopting PM will alter the approach to diagnosis and treatment, and will lead to increased participation of the patient during and after treatment. For example, active surveillance in prostate cancer gives patients the choice on if they would like curative treatment immediately, with potential complications and discomfort, or wait until there is signs of disease progression. This aspect of PM incorporates the circumstances of the patient as an influence on the appropriate treatment strategy for them as a person, not just as a patient.
The Visionary Leader Upfront
Sajung Yun is the Chief Executive Officer of Predictiv.